Skip to main content
NovMetaPharma Co., Ltd. logo

NovMetaPharma Co., Ltd. — Investor Relations & Filings

Ticker · 229500 ISIN · KR7229500004 KO Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2024-08-13 Regulatory Filings
Country KR South Korea
Listing KO 229500

About NovMetaPharma Co., Ltd.

http://www.novmeta.com/

NovMetaPharma Co., Ltd. is a biopharmaceutical company specializing in the research and development of first-in-class drugs with differentiated mechanisms. The company focuses on creating novel therapeutics for metabolic and fibrotic diseases, addressing significant unmet medical needs. Its main pipeline includes drug candidates for type 2 diabetes (NovDB2), obesity (NovOB), chronic kidney disease (NovRD), and fibrosis (NovFS). The company's lead assets in clinical development are Cyclo-Z and CHP. NovMetaPharma aims to develop innovative treatments by leveraging its core research teams and efficient development systems to target the root causes of these complex conditions.

Recent filings

Filing Released Lang Actions
특허권취득(자율공시) (시클로-히스프로의 폴리모픽형 물질 특허)
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement regarding the acquisition of a patent ('특허권 취득') by the company NovMetaPharma. It details the patent name, content, and its application in the company's drug development pipeline. Since this is a specific corporate disclosure regarding intellectual property that does not fit into financial reporting, governance, or shareholder meeting categories, it falls under the general regulatory filing category.
2024-08-13 Korean
특허권취득(자율공시) (아릴에텐 화합물의 제조방법)
Regulatory Filings Classification · 100% confidence The document is a short, voluntary disclosure regarding the acquisition of a patent for a manufacturing process of a chemical compound (DN434). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a regulatory disclosure of a corporate event (patent acquisition) that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2024-08-07 Korean
특허권취득(자율공시)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a pharmaceutical composition. It details the patent name, content, and strategic utilization plan. Since this is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, dividend, or management change categories, it falls under the general regulatory filing category.
2024-07-30 Korean
특허권취득(자율공시)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a pharmaceutical composition. It details the patent name, content, patent holder, and utilization plan. Since this is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, governance, or shareholder-specific categories, it falls under the general regulatory filing category.
2024-07-02 Korean
특허권취득(자율공시) (METHOD OF TREATING FIBROSIS)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a fibrosis treatment method by NovMetaPharma. It details the patent name, content, and strategic application. Since this is a specific corporate announcement regarding a business development (patent acquisition) that does not fit into financial reporting, governance, or shareholder meeting categories, it falls under the general regulatory announcement category.
2024-06-25 Korean
특허권취득(자율공시) (CHP(사이클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물)
Regulatory Filings Classification · 100% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for a pharmaceutical composition. It details the patent name, content, and strategic use. Since it does not fit into specific categories like financial reports, dividends, or management changes, and is a regulatory disclosure of corporate activity, it falls under the general regulatory filing category.
2024-06-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.